文献速递肝病胰腺与胆道疾病消化内镜

重型COVID-19后胆管病的临床特征与预后意义

Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该回顾性研究纳入2020年3月至8月因肝酶异常接受肝病会诊的COVID-19患者,识别出12例以血清ALP显著升高和磁共振胆胰管成像胆管损伤为特征的胆管病。胆管病发生于COVID-19诊断后平均118天,5例因持续黄疸、肝衰竭或反复胆管炎被转诊评估肝移植,1例成功接受活体肝移植。

要点

  • 重型COVID-19康复者出现ALP显著升高需警惕胆管病。
  • MRCP可见肝内胆管串珠样改变、胆管壁增厚强化及胆管周围高信号。
  • 胆管病可致进行性胆管损伤和肝衰竭,部分需肝移植。

核心结论

  • 胆管病是重型COVID-19的晚期并发症,具有进行性胆管损伤和肝衰竭的潜在风险。

研究设计与样本

  • 回顾性研究,纳入2020年3月1日至8月15日入院、因肝酶异常接受肝病会诊的COVID-19患者,共12例。

主要发现

  • 12例中11男1女,平均年龄58岁,从COVID-19诊断至胆管病诊断平均118天。
  • 峰值中位血清ALT为661 U/L,峰值中位血清ALP为1855 U/L。
  • MRCP显示肝内胆管串珠样改变11/12(92%)、胆管壁增厚强化7/12(58%)、胆管周围弥散高信号10/12(83%)。
  • 4例肝活检显示急性和/或慢性大胆管梗阻,无明确胆管丢失。
  • 5例因持续黄疸、肝功能不全和/或反复细菌性胆管炎被转诊考虑肝移植,1例成功接受活体肝移植。

关键数值与推荐

  • 胆管损伤定义为血清ALP>3倍正常上限且MRCP异常。

临床怎么用

  • 对重型COVID-19康复者出现ALP显著升高应行MRCP评估胆管损伤。
  • 识别持续黄疸、肝功能不全或反复胆管炎者,及时评估肝移植指征。

局限性

  • 回顾性研究,样本量小(12例),仅纳入因肝酶异常接受肝病会诊的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 virus, is a predominantly respiratory tract infection with the capacity to affect multiple organ systems. Abnormal liver tests, mainly transaminase elevations, have been reported in hospitalized patients. We describe a syndrome of cholangiopathy in patients recovering from severe COVID-19 characterized by marked elevation in serum alkaline phosphatase (ALP) accompanied by evidence of bile duct injury on imaging. METHODS: We conducted a retrospective study of COVID-19 patients admitted to our institution from March 1, 2020, to August 15, 2020, on whom the hepatology service was consulted for abnormal liver tests. Bile duct injury was identified by abnormal liver tests with serum ALP > 3x upper limit of normal and abnormal findings on magnetic resonance cholangiopacreatography. Clinical, laboratory, radiological, and histological findings were recorded in a Research Electronic Data Capture database. RESULTS: Twelve patients were identified, 11 men and 1 woman, with a mean age of 58 years. Mean time from COVID-19 diagnosis to diagnosis of cholangiopathy was 118 days. Peak median serum alanine aminotransferase was 661 U/L and peak median serum ALP was 1855 U/L. Marked elevations of erythrocyte sedimentation rate, C-reactive protein, and D-dimers were common. Magnetic resonance cholangiopacreatography findings included beading of intrahepatic ducts (11/12, 92%), bile duct wall thickening with enhancement (7/12, 58%), and peribiliary diffusion high signal (10/12, 83%). Liver biopsy in 4 patients showed acute and/or chronic large duct obstruction without clear bile duct loss. Progressive biliary tract damage has been demonstrated radiographically. Five patients were referred for consideration of liver transplantation after experiencing persistent jaundice, hepatic insufficiency, and/or recurrent bacterial cholangitis. One patient underwent successful living donor liver transplantation. DISCUSSION: Cholangiopathy is a late complication of severe COVID-19 with the potential for progressive biliary injury and liver failure. Further studies are required to understand pathogenesis, natural history, and therapeutic interventions.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol. 2021. PMID: 33993134. doi:10.14309/ajg.0000000000001264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。